S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

ABSTRACT:

SUBMITTER: Sureda A 

PROVIDER: S-EPMC10428422 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature